Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a report released on Thursday, The Fly reports. They currently have a $23.00 price objective on the specialty pharmaceutical company’s stock, down from their prior price objective of $55.00. Stifel Nicolaus’ target price suggests a potential upside of 15.40% from the stock’s current price.
Other equities research analysts have also recently issued reports about the company. Mizuho restated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, August 7th. ValuEngine cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. Cowen set a $50.00 price objective on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th. Zacks Investment Research raised Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Jefferies Financial Group lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price objective for the stock from $46.00 to $23.00 in a report on Wednesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $46.50.
NASDAQ SUPN opened at $19.93 on Thursday. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of 9.72, a PEG ratio of 1.00 and a beta of 1.63. Supernus Pharmaceuticals has a one year low of $19.35 and a one year high of $49.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.72 and a quick ratio of 2.53. The business’s fifty day moving average is $27.10 and its 200-day moving average is $30.43.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, November 5th. The specialty pharmaceutical company reported $0.54 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.59 by ($0.05). Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The firm had revenue of $102.14 million during the quarter, compared to the consensus estimate of $108.70 million. During the same quarter in the prior year, the firm posted $0.52 earnings per share. The company’s revenue was down .8% on a year-over-year basis. Research analysts expect that Supernus Pharmaceuticals will post 2.16 EPS for the current fiscal year.
In other news, CEO Jack A. Khattar bought 7,200 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was acquired at an average price of $26.39 per share, with a total value of $190,008.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.57% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Supernus Pharmaceuticals by 0.9% during the second quarter. Vanguard Group Inc. now owns 5,345,217 shares of the specialty pharmaceutical company’s stock worth $176,873,000 after purchasing an additional 49,676 shares in the last quarter. Rice Hall James & Associates LLC boosted its holdings in Supernus Pharmaceuticals by 35.1% during the second quarter. Rice Hall James & Associates LLC now owns 1,351,286 shares of the specialty pharmaceutical company’s stock worth $44,714,000 after purchasing an additional 350,905 shares during the last quarter. Macquarie Group Ltd. boosted its holdings in Supernus Pharmaceuticals by 8.5% during the second quarter. Macquarie Group Ltd. now owns 1,079,001 shares of the specialty pharmaceutical company’s stock worth $35,705,000 after purchasing an additional 84,846 shares during the last quarter. Neumeier Poma Investment Counsel LLC boosted its holdings in Supernus Pharmaceuticals by 1.1% during the second quarter. Neumeier Poma Investment Counsel LLC now owns 957,401 shares of the specialty pharmaceutical company’s stock worth $31,680,000 after purchasing an additional 10,170 shares during the last quarter. Finally, Provident Investment Management Inc. boosted its holdings in Supernus Pharmaceuticals by 13.8% during the second quarter. Provident Investment Management Inc. now owns 726,333 shares of the specialty pharmaceutical company’s stock worth $24,034,000 after purchasing an additional 88,099 shares during the last quarter. Hedge funds and other institutional investors own 99.14% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.